Oxytocin-dependent reopening of a social reward learning critical period with MDMA
This mice study investigates the restoration/regulation of social reward learning for patients with long-term depression using MDMA. The findings point towards the potential of understanding the pathogenesis of neurodevelopmental diseases, which are defined by social impairments, and of disorders that are effected by social influence or are a consequence of social injury.
Authors
- Nardou, R.
- Lewis, E. M.
- Rothhaas, R.
Published
Abstract
A critical period is a developmental epoch during which the nervous system is expressly sensitive to specific environmental stimuli that are required for proper circuit organization and learning. Mechanistic characterization of critical periods has revealed an important role for exuberant brain plasticity during early development, and for constraints that are imposed on these mechanisms as the brain matures. In disease states, closure of critical periods limits the ability of the brain to adapt even when optimal conditions are restored. Thus, identification of manipulations that reopen critical periods has been a priority for translational neuroscience. Here we provide evidence that developmental regulation of oxytocin-mediated synaptic plasticity (long-term depression) in the nucleus accumbens establishes a critical period for social reward learning. Furthermore, we show that a single dose of (+/−)-3,4-methylendioxymethamphetamine (MDMA) reopens the critical period for social reward learning and leads to a metaplastic upregulation of oxytocin-dependent long-term depression. MDMA-induced reopening of this critical period requires activation of oxytocin receptors in the nucleus accumbens, and is recapitulated by stimulation of oxytocin terminals in the nucleus accumbens. These findings have important implications for understanding the pathogenesis of neurodevelopmental diseases that are characterized by social impairments and of disorders that respond to social influence or are the result of social injury.
Research Summary of 'Oxytocin-dependent reopening of a social reward learning critical period with MDMA'
Introduction
A critical period denotes a developmental window when the nervous system is highly sensitive to particular environmental stimuli required for appropriate circuit formation and learning. Earlier work has shown that exuberant plasticity during early development and subsequent maturation-imposed constraints shape these windows, and that once closed they can limit adaptive responses in disease. In this context, oxytocin (OT) signalling in the nucleus accumbens (NAc) has been implicated in juvenile social reward learning via a presynaptically expressed long-term depression (LTD) of excitatory synapses. Nardou and colleagues set out to test whether developmental regulation of OT-dependent synaptic plasticity establishes a critical period for social reward learning, and whether that period can be reopened. They examined the maturational trajectory of social conditioned place preference (social CPP) across mouse ages, tested age-dependent expression of OT-LTD in the NAc, and asked whether MDMA (±3,4-methylenedioxymethamphetamine) or direct stimulation of OT terminals can reinstate juvenile-like plasticity and behaviour in adults. The study aims to link cellular mechanisms in the NAc with behavioural critical-period regulation and to probe mechanistic requirements for any reopened window.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Full Text PDF
Full Paper PDF
Create a free account to open full-text PDFs.
Study Details
- Study Typeindividual
- Journal
- Compound
- Topics
- APA Citation
Nardou, R., Lewis, E. M., Rothhaas, R., Xu, R., Yang, A., Boyden, E., & Dölen, G. (2019). Oxytocin-dependent reopening of a social reward learning critical period with MDMA. Nature, 569(7754), 116-120. https://doi.org/10.1038/s41586-019-1075-9
References (3)
Papers cited by this study that are also in Blossom
Yazar-Klosinski, B., Mithoefer, M. C. · Clinical Pharmacology and Therapeutics (2016)
Mithoefer, A. T., Mithoefer, M. C., Feduccia, A. A. et al. · Lancet Psychiatry (2018)
Young, M. B., Norrholm, S. D., Khoury, L. M. et al. · Psychopharmacology (2017)
Cited By (30)
Papers in Blossom that reference this study
Thuery, G., Crossen, F., Mc Loone, D. et al. · Therapeutic Advances in Psychopharmacology (2026)
Jacobs, E., Zahid, Z., Hinkle, J. et al. · BMJ (2026)
Lu, O. D., White, K., Raymond, K. et al. · Biorxiv (2025)
Agnorelli, C., Spriggs, M. J., Godfrey, K. et al. · Preprints (2024)
Lewis, E. C., Jaeger, A., Girn, M. et al. · Journal of Psychopharmacology (2024)
Haggarty, C. J., Bershad, A. K., Kumar, M. K. et al. · European Journal of Neurology (2024)
Tiwari, P., Sayali, C., Doss, M. K. et al. · Psychedelic Medicine (2023)
Nardou, R., Sawyer, E., Song, Y. J. et al. · Nature (2023)
Carhart-Harris, R. L., Chandaria, S., Erritzoe, D. E. et al. · Neuropharmacology (2023)
Ponomarenko, P., Seragnoli, F., Calder, A. et al. · Journal of Psychopharmacology (2023)
Show all 30 papersShow fewer
Jones, G. M., Lipson, J., Wang, E. · Scientific Reports (2023)
Singleton, S. P., Wang, J. B., Mithoefer, A. T. et al. · Frontiers in Psychiatry (2023)
Christie, D., Yazar-Klosinski, B., Nosova, E. et al. · Frontiers in Psychiatry (2022)
Traynor, J. M., Roberts, D. E., Ross, S. et al. · Focus (2022)
van Elk, M., Yaden, D. B. · Neuroscience and Biobehavioral Reviews (2022)
Belser, A. B. · Frontiers in Psychology (2022)
Nayak, S., Griffiths, R. R. · Frontiers in Psychology (2022)
Sarparast, A., Thomas, K., Malcolm, B. et al. · Psychopharmacology (2022)
Rieser, N. M., Herdener, M. ;., Preller, K. H. · Current Topics in Behavioral Neurosciences (2021)
Luoma, J. B., Lear, M. K. · Frontiers in Psychiatry (2021)
Yehuda, R., Lepow, L., Morishita, H. · Frontiers in Neuroscience (2021)
Chaliha, D., Mamo, J. C., Albrecht, M. et al. · Current Neuropharmacology (2021)
Mitchell, J., Bogenschutz, M. P., Lilienstein, A. et al. · Nature Medicine (2021)
Nichols, D. E., Walter, H. · Pharmacopsychiatry (2020)
Hibicke, M., Gobbi, G. · Journal of Neuroscience (2020)
Krediet, E., Bostoen, T., Breeksema, J. J. et al. · International Journal of Neuropsychopharmacology (2020)
Barrett, F. S., Doss, M. K., Sepeda, N. D. et al. · Scientific Reports (2020)
Bahji, A., Forsyth, A., Groll, D. et al. · Progress in Neuro-Psychopharmacology and Biological Psychiatry (2020)
Preller, K. H., Vollenweider, F. X. · Frontiers in Psychiatry (2019)
Feduccia, A. A., Jerome, L., Yazar-Klosinski, B. et al. · Frontiers in Psychiatry (2019)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.